The molecule in question is miR-486, a microRNA that is unusually abundant in cardiac tissue. MicroRNAs are tiny non-coding RNA strands, roughly twenty-two nucleotides long, that do not carry protein-building instructions themselves. Instead, they act as molecular dimmer switches, binding to complementary sequences in messenger RNA and preventing those messages from being translated into protein. Because a single microRNA can regulate dozens of different targets simultaneously, these molecules sit at powerful control points in cellular networks. Previous work had shown that miR-486 levels drop sharply in ischaemic heart tissue, but the functional consequences of that loss, and the mechanisms behind any protective effect, remained unclear until this study.

To test whether restoring miR-486 could protect the heart, the researchers used a clever delivery vehicle. They packaged the microRNA inside an adeno-associated virus, AAV9, and injected it into the tail veins of rats three weeks before inducing a heart attack. This viral vector is the same platform used in several approved gene therapies because it efficiently transduces cardiac tissue and produces sustained expression of its cargo. Once the microRNA was established in the myocardium, the team surgically ligated the left anterior descending coronary artery for thirty minutes and then released the ligature to allow reperfusion, faithfully recreating the clinical scenario of a heart attack followed by emergency revascularisation.

The results were striking. Rats that received the miR-486 vector showed significantly better cardiac function seventy-two hours after reperfusion, with higher left ventricular ejection fraction and fractional shortening measured by echocardiography. Infarct size, quantified by staining viable tissue with triphenyltetrazolium chloride, was markedly reduced compared with control animals. Histological examination revealed less tissue damage and reduced early collagen deposition, suggesting that miR-486 restrains the initial stages of adverse matrix remodelling that can lead to fibrosis over time. In short, a single microRNA delivered before the injury was enough to measurably preserve heart structure and function.

But the researchers wanted to understand how this protection worked at the molecular level, so they turned to a cell model. They exposed H9c2 cardiomyocytes, a rat cardiac cell line, to oxygen-glucose deprivation followed by reoxygenation, a laboratory technique that mimics ischaemia and reperfusion in a dish. Under these conditions, they transfected cells with either a miR-486 mimic to boost the microRNA or an inhibitor to block it. Western blotting then revealed the protein changes that followed. When miR-486 was boosted, levels of two proteins called FOXO1 and PTEN dropped sharply. When miR-486 was blocked, both proteins rose even higher than they did under ischaemic stress alone.

To confirm that FOXO1 and PTEN were direct targets rather than indirect consequences, the team performed dual-luciferase reporter assays. They cloned the three-prime untranslated regions of both genes, the segments where microRNAs typically bind, into plasmids that drive luciferase expression. When they co-transfected these reporters with the miR-486 mimic, luciferase activity dropped for the wild-type versions of both FOXO1 and PTEN reporters. But when they mutated the predicted binding sites, the inhibitory effect vanished. This is the gold-standard evidence that a microRNA directly targets a specific gene, and it proved that miR-486 binds FOXO1 and PTEN at their predicted sequences.

With the targets confirmed, the researchers traced the downstream consequences. Both FOXO1, a stress-responsive transcription factor, and PTEN, a lipid phosphatase, are established negative regulators of the AKT/mTOR pathway, a central pro-survival signalling cascade in cardiomyocytes. When miR-486 suppressed FOXO1 and PTEN, phosphorylation of AKT and its downstream targets S6K and 4EBP1 rose significantly, indicating that the pro-survival pathway had been reactivated. Conversely, when miR-486 was blocked, phosphorylation of these molecules fell even further. The team then used pharmacological inhibitors, MK2206 to block AKT and rapamycin to block mTOR, and found that either inhibitor partially abolished the protective effects of the miR-486 mimic, confirming that AKT/mTOR activation is essential for the cardioprotection.

The functional readout of this signalling was equally compelling. Under oxygen-glucose deprivation, cardiomyocytes normally activate two destructive programmes simultaneously. The first is apoptosis, measured by rising ratios of Bax to Bcl-2 and cleaved caspase-3 to total caspase-3. The second is excessive autophagy, the cellular recycling programme that becomes maladaptive when overstimulated, tracked by rising Beclin 1 and LC3-II levels alongside falling p62. When miR-486 was boosted, both programmes were suppressed in parallel. When it was blocked, both intensified. To rule out the possibility that altered LC3-II levels simply reflected impaired autophagic degradation rather than genuine changes in autophagic activity, the team used bafilomycin A1, a drug that blocks lysosomal LC3-II turnover. The results showed that miR-486 genuinely attenuates excessive autophagic flux rather than merely causing LC3-II to accumulate artificially.

Rescue experiments sealed the mechanistic argument. When the researchers silenced FOXO1 or PTEN with siRNA in cells where miR-486 had been pharmacologically blocked, the destructive apoptosis and autophagy programmes were partially reversed. This proved that FOXO1 and PTEN are not merely passive readouts of miR-486 activity but active mediators of its protective effect. The picture that emerges is a coherent regulatory axis: miR-486 sits at the top, directly repressing FOXO1 and PTEN, which in turn releases the brakes on AKT/mTOR signalling, which then co-ordinately suppresses both apoptosis and maladaptive autophagy in the ischaemic cardiomyocyte.

The clinical implications of this work are substantial. MIRI remains a stubborn clinical challenge because reperfusion itself inflicts damage that no current therapy can prevent, substantially reducing the benefits of timely revascularisation in acute myocardial infarction. The identification of the miR-486/FOXO1/PTEN/AKT/mTOR axis as a cardioprotective mechanism opens a potential therapeutic avenue, and the AAV delivery platform used in this study is already validated in human gene therapy. However, the authors caution that several questions remain. Only gain-of-function was tested in vivo, loss-of-function studies are needed, the mechanistic work was performed in a cell line rather than primary cardiomyocytes, and long-term effects on fibrosis and ventricular remodelling require evaluation at later time points. Because microRNAs typically regulate multiple targets, other downstream effectors of miR-486 may also contribute to its cardioprotective actions. Nevertheless, the study represents a significant advance in understanding how a single cardiac-enriched microRNA can co-ordinate multiple cell death pathways through one elegant signalling circuit, and it positions miR-486 as a promising candidate for future therapeutic development against one of cardiology’s most neglected targets.

Subject of Research: miR-486 attenuates myocardial ischaemia/reperfusion injury by inhibiting apoptosis and autophagy activation via the FOXO1/PTEN/AKT/mTOR axis

Article Title: miR-486 attenuates myocardial ischaemia/reperfusion injury by inhibiting apoptosis and autophagy activation via the FOXO1/PTEN/AKT/mTOR axis

Article References: Xu, L., Xu, W., Li, G., & Sun, Q. (2026). miR-486 attenuates myocardial ischaemia/reperfusion injury by inhibiting apoptosis and autophagy activation via the FOXO1/PTEN/AKT/mTOR axis. Molecular Biology Reports, 53(1), Article 1745. https://doi.org/10.1007/s11033-026-12913-5

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12913-5

Keywords: miR-486, attenuates, myocardial, ischaemia, reperfusion, injury, inhibiting, apoptosis, autophagy, activation, FOXO1, PTEN